Passage Bio (PASG)
(Delayed Data from NSDQ)
$1.35 USD
+0.04 (3.05%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $1.39 +0.04 (2.96%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PASG 1.35 +0.04(3.05%)
Will PASG be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for PASG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PASG
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
PASG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PASG
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
New Innovation / R&D Risk for Passage Bio, Inc. – What’s the Latest?
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights